VUITY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610518 | ABBVIE | Presbyopia treatments |
Apr, 2039
(14 years from now) | |
| US11285134 | ABBVIE | Presbyopia treatments |
Apr, 2039
(14 years from now) | |
Vuity is owned by Abbvie.
Vuity contains Pilocarpine Hydrochloride.
Vuity has a total of 2 drug patents out of which 0 drug patents have expired.
Vuity was authorised for market use on 28 October, 2021.
Vuity is available in solution;ophthalmic dosage forms.
Vuity can be used as use of vuity for the treatment of presbyopia in adults.
The generics of Vuity are possible to be released after 24 April, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-187) | Mar 28, 2026 |
| New Product(NP) | Oct 28, 2024 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
How can I launch a generic of VUITY before it's drug patent expiration?
More Information on Dosage
VUITY family patents
